Kevzara (sarilumab)

P2, N=105, Recruiting, NYU Langone Health | N=69 --> 105 | Trial completion date: Dec 2025 --> Feb 2028 | Trial primary completion date: Jun 2025 --> Aug 2026

P4, N=300, Not yet recruiting, Sanofi

Recent postmarketing surveillance (PMS) data on the safety and effectiveness of sarilumab (SAR) in Japanese patients with RA, along with PMS data from Japan and registry data from France and Germany of tocilizumab (TCZ), provide valuable insights for both current and future management of RA. While the effectiveness of TCZ was somewhat lower in older patients compared with younger ones, the effectiveness of SAR was similar across age groups. Consequently, the use of anti-IL-6R antibodies is anticipated to expand to other IMIDs beyond RA, particularly in increasingly superaged societies worldwide.

P2, N=300, Not yet recruiting, Regeneron Pharmaceuticals

For RA, 34.2% of patients were difficult to treat (D2T) (98 pt), 54.8% (157 pt) were in monotherapy (tocilizumab-sarilumab-upadacitinib-filgotinib). Abatacept was the most prescribed treatment in RF and ACPA-positive patients and in those with ILD. The anti-IL-17A secukinumab was prescribed in 12% of SpA, of which 71% had enthesitis and dactylitis (14 pt). Ixekizumab was prescribed in 10.4% of PsA patients over 65 years with previous CV events, enthesitis, and dactylitis (21 pt). Apremilast was present in 71% of PsA with previous cancer...The cross-sectional analysis of prescriptions in patients with RA, SpA, and PsA demonstrates how the ITABIO recommendations can guide towards the correct appropriateness of prescription. RA and especially D2T-RA remains the disease with the greatest therapeutic failures, with the highest percentage of monotherapy (anti-IL-6 and Jak-i) and of discontinuation of MTX.

P1/2, N=612, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Apr 2027 --> Nov 2027

P3, N=400, Recruiting, University of Nebraska | Trial completion date: Mar 2028 --> Mar 2029 | Trial primary completion date: Mar 2027 --> Mar 2028

The unbiased analysis of serum proteins identified biomarkers most predictive of anti-IL-6R and anti-TNF-α at different timepoints that could explain the difference in the response rate in patients with RA. Further, both biomarker and pathway results highlighted a differentiated mode of action of both treatments.

P1/2, N=890, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Feb 2026

Among approved DMT for MS and RA, teriflunomide and anti-CD20 therapies are the most suitable options for moderately or highly active MS with comorbid RA. Cladribine may also be considered, while TNFα inhibitors are contraindicated.

P2, N=220, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting

P2/3, N=239, Completed, Assistance Publique - Hôpitaux de Paris | Unknown status --> Completed